Abstract
The acetylator phenotype was determined in 100 patients with breast cancer and 100 control female subjects using isoniazid. The proportion of fast acetylators in the breast cancer patients (43%) was not significantly different from the control group (43%). We conclude that acetylator phenotype is unlikely to be an important determinant of the risk of developing breast cancer.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Webster, D., Flook, D., Jenkins, J. et al. Drug acetylation in breast cancer. Br J Cancer 60, 236–237 (1989). https://doi.org/10.1038/bjc.1989.260
Issue Date:
DOI: https://doi.org/10.1038/bjc.1989.260
- Springer Nature Limited
This article is cited by
-
Meat intake and bladder cancer in a prospective study: a role for heterocyclic aromatic amines?
Cancer Causes & Control (2008)